Drug intelligence / Profile preview

HS-10542

Development stage: Phase 2
Lead developer: Hansoh Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

HS-10542 is a **Category 1 innovative small molecule drug** developed by Jiangsu Hansoh Pharmaceutical. It is being studied for immune system, hemic and lymphatic, and urogenital diseases, specifically targeting **paroxysmal nocturnal hemoglobinuria (PNH)** and **immunoglobulin A nephropathy (IgAN)** (also known as IgA glomerulonephritis). The drug has received clinical trial approval from the National Medical Products Administration (NMPA) of China. Currently, HS-10542 is in Phase 1 clinical trials; studies are focusing on its safety, tolerability, pharmacokinetics, and the impact of food on pharmacokinetics in healthy volunteers. The exact target and mechanism of action have not been disclosed publicly[1][2][4][5][6][7][8][10].

Other names: HS-10542HS10542HS 10542

Targets

CFB (Complement Factor B)

Beyond the preview

Go deeper on HS-10542.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HS-10542.

Explore the full profile